InvestorsHub Logo
Followers 85
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: north40000 post# 199769

Monday, 12/15/2014 11:56:55 AM

Monday, December 15, 2014 11:56:55 AM

Post# of 346182
We may be able to but either way, if he is out.... and Soon-Shiong moving faster than any BP or CALICO... this effort by Soon-Shiong should help speed others along as well. Good for Peregrine either way, because this is not a time where anyone can just sit around and wait...

We know Peregrine has not just been sitting around as they have employees working for Takeda at the same time, working with Ambit Biosciences at the same time and countless others....

As for Greece and their high # of patients in SunRise may be attributed to these facts, and we know that Sonia Perez (Head of Immune Monitoring Lab at Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital) seems to have a good working relationship with Nikoletta who left the East Coast to all of a sudden jump at an opportunity at Peregrine on the West Coast and looks to have global demand plans for Bavituximab.

Cancer Immunology and Immunotherapy Center (CIIC) – Designing robust immunotherapies against cancer

The Cancer Immunology and Immunotherapy Center (CIIC) was founded in 1996 to investigate the field of cancer immunology, which is based on the premise that the body's immune system can be mobilized against cancer. This field, which CIIC helped progress, has provided the basis for the development of cancer immunotherapy. Research at the Cancer Immunology and Immunotherapy Center (CIIC) is dedicated to experimental cancer research, in close collaboration with the adjacent "Saint Savas" Cancer Hospital.

Drawing upon the expertise of internationally renowned researchers and clinicians from the Schools of Biology and Medicine, the Cancer Immunology and Immunotherapy Center is at the forefront of today's advances in cancer research and cancer immunotherapy.

Interdisciplinary research by CIIC experts in cancer biology, cancer immunology and immunotherapy and other fields is yielding critical insights into the origins of cancer, while collaborations between the lab and clinic are working to move the most promising discoveries into improved diagnostic, treatment and prevention strategies.

Patients seeking care at St Savas Cancer Hospital may gain early access to these emerging therapies—and the benefits that they may offer—through the center’s clinical trials program.

http://www.ciic.gr/portal/



"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News